What is COAG's 12-month stock price target?

Hemab Therapeutics Holdings Inc. (COAG) carries a 12-month consensus base price target of $41.37 (+0.5% from $41.18), with a bull-case target of $58.19 and a bear-case floor of $32.27.

Stock Ratings / Health Care / COAG / forecast

VIR (40) MESO (51) VCEL (58) ALVO (52) ⌘ Pro Terminal →

Hemab Therapeutics Holdings Inc. (COAG) 12-Month Stock Forecast & Price Target Cone

Q: Is COAG stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates COAG C- (Hold — HOLD) with an RQD Confidence score of 59/100.

$41.18 -0.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $41.05

Hemab Therapeutics Holdings Inc. (COAG) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $1.94B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on COAG Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is COAG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Hemab Therapeutics Holdings Inc. (NASDAQ: COAG) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $41.18 (-0.65% 1D, market cap $1.94B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, COAG ranks #168 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does COAG compare to VIR and MESO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), COAG carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VIR (Vir Biotechnology Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.93B) and MESO (Mesoblast Limited) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $1.97B). Among the 5-stock peer group, VCEL leads on earnings multiple (133.0x) while VCEL leads on capital efficiency (3.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for COAG?

▼

Per COAG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002114044), Hemab Therapeutics Holdings Inc. generated $81.8M in revenue, $0 in net income, and $0 in free cash flow against $194.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $41.05 (-0.31%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 66.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COAG)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY COAG SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$29.80+14.7% Next Q

Q2 (-2Q)

Grade C-$34.17+12.4% Next Q

Q3 (-1Q)

Grade C$38.40+7.2% Next Q

Current

Grade C-$41.18+0.2% Hist 90D α

Trajectory: C- (51) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the COAG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, COAG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($37.62) or 200D SMA ($36.85) invalidates the momentum regime and cuts Target Base ($41.37) toward Bear Floor ($32.27).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $COAG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “COAG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your COAG Position Size: $10,000

Shares at $41.18: 242.8 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $32.27

$7,836

$-2,164 (-21.6%)

12M Consensus BaseTarget $41.37

$10,046

+$46 (+0.5%)

12M Bull Case BreakoutTarget $58.19

$14,131

+$4,131 (+41.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$43	74%	A
Goldman SachsSector Coverage Lead	BUY	$55	69%	B
JP MorganUS Large-Cap Research	HOLD	$37	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (COAG Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

COAG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +62.51%⚡ TESTING RESISTANCE

2026-11-03O $40.42H $41.45L $40.42C $41.18VOL 765.6K

RES: $42.60SUP: $28.19SMA50: $37.62SMA200: $36.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

COAG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 COAG Butterfly Map → + Track COAG →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on COAG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for COAG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for COAG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COAG)

Health Care Rank #168 of 1015 ⚔️ VIR vs COAG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (COAG vs. VIR, MESO, VCEL, ALVO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Hemab Therapeutics Holdings Inc. (COAG) ranks #168 by composite RQD confidence (59/100, grade C-) and #261 by equity capitalization ($1.94B). Within this direct 5-issuer industry benchmark cohort, VCEL leads on earnings valuation at 133.0x trailing P/E, while VCEL leads on capital efficiency and profitability with 3.4% ROIC and 74.4% gross margin. COAG currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
COAG ACTIVE Hemab Therapeutics Holdings Inc.	C-	59/100	—	—	—	-0.65%	$1.94B	Benchmark Subject
VIR Vir Biotechnology Inc.	D-	40/100	—	96.0%	-35.0%	-2.65%	$1.93B	/vir-vs-coag →
MESO Mesoblast Limited	D	51/100	—	—	—	-4.09%	$1.97B	/meso-vs-coag →
VCEL Vericel Corporation	D+	58/100	133.0x	74.4%	3.4%	+0.62%	$2.06B	/vcel-vs-coag →
ALVO Alvotech	D+	52/100	—	—	—	-3.66%	$1.82B	/alvo-vs-coag →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002114044 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hemab Therapeutics Holdings Inc. (COAG) reported GAAP revenue of $81.8M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, COAG closed FY2025 with $194.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$81.8M	$0	—	—	$194.8M	—

3. COAG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is COAG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does COAG compare to VIR and MESO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for COAG?

Where is COAG trading relative to its 50-day, 200-day, and 52-week technical levels?

COAG last traded at $41.18 (-0.65% on volume of 343,889 shares), positioning the stock +9.46% above its 50-day simple moving average ($37.62) and +11.75% above its 200-day simple moving average ($36.85). Across its 52-week range of $23.00 to $55.42, COAG sits at the 56.1% percentile with a 14-day RSI of 65.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($36.03 to $46.33).

Direct Sub-Reports: COAG RQD Cockpit COAG 12M Forecast COAG Earnings & Move COAG Dividends & DRIP COAG Insiders & 13F COAG Whale Options COAG Profit Sankey COAG News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

COAG — Hemab Therapeutics Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Hemab Therapeutics Holdings Inc. (COAG) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $41.18 (-0.65% 1D, market capitalization $1.94B).

Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (15/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Hemab Therapeutics Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. It operates with a market capitalization of $1.9B. — for product lines, customers, or revenue model specifics.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Hemab Therapeutics Holdings Inc. (COAG) reported $81.8M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $194.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C- • RQD 59/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of — and institutional whale pillar of 15/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $23.00 – $55.42 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies, no links, and no proprietary signals. Sector-level correlations beyond the stated beta of 1.0 are not provided. The primary second-order watch item is the lock-up expiration on 28-OCT-2026, which could add supply to the market near the stated data date and may be a pressure point on trading dynamics.

Key Question #1: Can COAG sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $81.8M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is COAG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

COAG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Hemab Therapeutics Holdings Inc. (COAG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to COAG Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

JPMorgan Initiates Hemab Therapeutics at Overweight With $70 Price Target

Yahoo Finance report covering Hemab Therapeutics Holdings Inc. (COAG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Hemab Therapeutics Holdings, Inc. Estimates – NASDAQ:COAG

TradingView report covering Hemab Therapeutics Holdings Inc. (COAG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 1d ago

27,442,910 Common Stock of Hemab Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 28-OCT-2026.

marketscreener.com report covering Hemab Therapeutics Holdings Inc. (COAG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Hemab Therapeutics (NASDAQ:COAG) Stock Price Up 8.4% - Here's What Happened